Cargando…
Improving Osteosarcoma Treatment: Comparative Oncology in Action
Osteosarcoma (OSA) is the most common pediatric malignant bone tumor. Although surgery together with neoadjuvant/adjuvant chemotherapy has improved survival for localized OSA, most patients develop recurrent/metastatic disease with a dismally poor outcome. Therapeutic options have not improved for t...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9783386/ https://www.ncbi.nlm.nih.gov/pubmed/36556464 http://dx.doi.org/10.3390/life12122099 |
_version_ | 1784857566503763968 |
---|---|
author | Tarone, Lidia Mareschi, Katia Tirtei, Elisa Giacobino, Davide Camerino, Mariateresa Buracco, Paolo Morello, Emanuela Cavallo, Federica Riccardo, Federica |
author_facet | Tarone, Lidia Mareschi, Katia Tirtei, Elisa Giacobino, Davide Camerino, Mariateresa Buracco, Paolo Morello, Emanuela Cavallo, Federica Riccardo, Federica |
author_sort | Tarone, Lidia |
collection | PubMed |
description | Osteosarcoma (OSA) is the most common pediatric malignant bone tumor. Although surgery together with neoadjuvant/adjuvant chemotherapy has improved survival for localized OSA, most patients develop recurrent/metastatic disease with a dismally poor outcome. Therapeutic options have not improved for these OSA patients in recent decades. As OSA is a rare and “orphan” tumor, with no distinct targetable driver antigens, the development of new efficient therapies is still an unmet and challenging clinical need. Appropriate animal models are therefore critical for advancement in the field. Despite the undoubted relevance of pre-clinical mouse models in cancer research, they present some intrinsic limitations that may be responsible for the low translational success of novel therapies from the pre-clinical setting to the clinic. From this context emerges the concept of comparative oncology, which has spurred the study of pet dogs as a uniquely valuable model of spontaneous OSA that develops in an immune-competent system with high biological and clinical similarities to corresponding human tumors, including in its metastatic behavior and resistance to conventional therapies. For these reasons, the translational power of studies conducted on OSA-bearing dogs has seen increasing recognition. The most recent and relevant veterinary investigations of novel combinatorial approaches, with a focus on immune-based strategies, that can most likely benefit both canine and human OSA patients have been summarized in this commentary. |
format | Online Article Text |
id | pubmed-9783386 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-97833862022-12-24 Improving Osteosarcoma Treatment: Comparative Oncology in Action Tarone, Lidia Mareschi, Katia Tirtei, Elisa Giacobino, Davide Camerino, Mariateresa Buracco, Paolo Morello, Emanuela Cavallo, Federica Riccardo, Federica Life (Basel) Commentary Osteosarcoma (OSA) is the most common pediatric malignant bone tumor. Although surgery together with neoadjuvant/adjuvant chemotherapy has improved survival for localized OSA, most patients develop recurrent/metastatic disease with a dismally poor outcome. Therapeutic options have not improved for these OSA patients in recent decades. As OSA is a rare and “orphan” tumor, with no distinct targetable driver antigens, the development of new efficient therapies is still an unmet and challenging clinical need. Appropriate animal models are therefore critical for advancement in the field. Despite the undoubted relevance of pre-clinical mouse models in cancer research, they present some intrinsic limitations that may be responsible for the low translational success of novel therapies from the pre-clinical setting to the clinic. From this context emerges the concept of comparative oncology, which has spurred the study of pet dogs as a uniquely valuable model of spontaneous OSA that develops in an immune-competent system with high biological and clinical similarities to corresponding human tumors, including in its metastatic behavior and resistance to conventional therapies. For these reasons, the translational power of studies conducted on OSA-bearing dogs has seen increasing recognition. The most recent and relevant veterinary investigations of novel combinatorial approaches, with a focus on immune-based strategies, that can most likely benefit both canine and human OSA patients have been summarized in this commentary. MDPI 2022-12-14 /pmc/articles/PMC9783386/ /pubmed/36556464 http://dx.doi.org/10.3390/life12122099 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Commentary Tarone, Lidia Mareschi, Katia Tirtei, Elisa Giacobino, Davide Camerino, Mariateresa Buracco, Paolo Morello, Emanuela Cavallo, Federica Riccardo, Federica Improving Osteosarcoma Treatment: Comparative Oncology in Action |
title | Improving Osteosarcoma Treatment: Comparative Oncology in Action |
title_full | Improving Osteosarcoma Treatment: Comparative Oncology in Action |
title_fullStr | Improving Osteosarcoma Treatment: Comparative Oncology in Action |
title_full_unstemmed | Improving Osteosarcoma Treatment: Comparative Oncology in Action |
title_short | Improving Osteosarcoma Treatment: Comparative Oncology in Action |
title_sort | improving osteosarcoma treatment: comparative oncology in action |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9783386/ https://www.ncbi.nlm.nih.gov/pubmed/36556464 http://dx.doi.org/10.3390/life12122099 |
work_keys_str_mv | AT taronelidia improvingosteosarcomatreatmentcomparativeoncologyinaction AT mareschikatia improvingosteosarcomatreatmentcomparativeoncologyinaction AT tirteielisa improvingosteosarcomatreatmentcomparativeoncologyinaction AT giacobinodavide improvingosteosarcomatreatmentcomparativeoncologyinaction AT camerinomariateresa improvingosteosarcomatreatmentcomparativeoncologyinaction AT buraccopaolo improvingosteosarcomatreatmentcomparativeoncologyinaction AT morelloemanuela improvingosteosarcomatreatmentcomparativeoncologyinaction AT cavallofederica improvingosteosarcomatreatmentcomparativeoncologyinaction AT riccardofederica improvingosteosarcomatreatmentcomparativeoncologyinaction |